Displaying drugs 1576 - 1600 of 1785 in total
Narasin
Narasin is an agent with coccidiostatic and antibacterial properties.
Experimental
Vet approved
Salinomycin
Vet approved
Lanopepden
Lanopepden has been used in trials studying the treatment of Pneumonia, Infections, Bacterial, Skin Diseases, Infectious, and Skin Infections, Bacterial.
Investigational
Isepamicin
Experimental
Etretinate
Etretinate is a medication used to treat severe psoriasis. It is a synthetic aromatic retinoid. The mechanism of action of etretinate is still incompletely understood although, like retinoic acid, it is thought to interfere with the terminal differentiation of keratinocytes. It is thought to bind to the retinoic acid receptors....
Withdrawn
Reidispongiolide A
Experimental
AMG-222
Investigational
4-Hydroxy-L-Threonine-5-Monophosphate
Experimental
Vincamine
Vincamine is a monoterpenoid indole alkaloid obtained from the leaves of Vinca minor with a vasodilatory property. Studies indicate that vincamine increases the regional cerebral blood flow.
Experimental
Lactobacillus brevis
Investigational
2-Oxo-3-Pentenoic Acid
Experimental
Latrunculin B
Latrunculin B is a 14-membered macrolide attached to 2-thiazolidinone moiety, isolated from Red Sea sponge Latrunculia magnifica.
Experimental
Tenivastatin
Experimental
WRR-112
Experimental
Paramethasone
A glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone. (From Martindale, The Extra Pharmacopoeia,...
Experimental
Ubenimex
Ubenimex (also known as bestatin) is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.
Investigational
Flurandrenolide acetate
Experimental
Raceanisodamine
Investigational
Otamixaban
Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
Investigational
Madecassoside
Experimental
Displaying drugs 1576 - 1600 of 1785 in total